Kidney — In Follow-up
The RAMPART platform trial has been designed to evaluate multiple treatments simultaneously, while adapting to a changing landscape as data on different agents and combinations
of agents emerges.
The aims for the initial research comparisons are as follows:
– Does treatment with either durvalumab alone or a combination of durvalumab and tremelimumab increase Disease Free Survival (DFS) compared with active monitoring
(Arm B vs Arm A, and Arms C vs Arm A respectively)?
– Does treatment with either durvalumab alone or a combination of durvalumab and tremelimumab increase Overall Survival (OS) compared with active monitoring in
patients classified as Leibovich high-risk (Arm B vs Arm A, and Arms C vs Arm A respectively)?
– Disease Free Survival (DFS) is defined as the interval from randomisation to first evidence of local recurrence, new primary RCC, distant metastases, or death from any cause, whichever occurs first.
– Overall Survival is defined as all-cause mortality, the time from randomisation to death from any cause (including RCC).